OptiNose News

Earnings Call Summary | OptiNose(OPTN.US) Q1 2024 Earnings Conference

The following is a summary of the OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript:Financial Performance:OptiNose reported a Q1 2024 net revenue of $14.9 million, a 26% increase compared to Q1 2

Futu NewsMay 18 04:45 · Conference Call

OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript

OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 17 19:55

Why Doximity Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket

Shares of Doximity, Inc. (NYSE:DOCS) rose sharply in today's pre-market trading reported stronger-than-expected financial results for the fourth quarter on Thursday.Doximity's fourth-quarter revenue i

BenzingaMay 17 07:19

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced tha

OptiNoseMay 16 23:00

Optinose Is Maintained at Buy by Lake Street

Optinose Is Maintained at Buy by Lake Street

Dow JonesMay 15 13:05

Optinose Price Target Cut to $3.00/Share From $4.00 by Lake Street

Optinose Price Target Cut to $3.00/Share From $4.00 by Lake Street

Dow JonesMay 15 13:05

Lake Street Maintains Buy on OptiNose, Lowers Price Target to $3

Lake Street analyst Thomas Flaten maintains OptiNose (NASDAQ:OPTN) with a Buy and lowers the price target from $4 to $3.

BenzingaMay 15 12:54

HC Wainwright & Co. Reiterates Buy on OptiNose, Maintains $5 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates OptiNose (NASDAQ:OPTN) with a Buy and maintains $5 price target.

BenzingaMay 15 10:14

OptiNose Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 346.43% HC Wainwright & Co. → $5 Reiterates Buy → Buy 04/29/2024 346.43% HC Wainwright & Co. →

BenzingaMay 15 10:12

Analysts Are Bullish on These Healthcare Stocks: ScPharmaceuticals (SCPH), Optinose (OPTN)

TipRanksMay 15 08:01

Optinose's XHANCE Expansion Drives Buy Rating Amidst Growth Potential

TipRanksMay 15 05:28

Q1 2024 OptiNose Inc Earnings Call

Yahoo FinanceMay 15 04:15

OptiNose Inc (OPTN) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...

Yahoo FinanceMay 15 02:07

OptiNose | 10-Q: Quarterly report

SEC announcementMay 14 08:04 · Announcements

Optinose Expects XHANCE Net Revenues For FY24 To Be Between $85M-$95M; Sees Average XHANCE Net Revenue Per Prescription To Exceed $230 (Prior View: $220)

Operating ExpensesThe Company expects total GAAP operating expenses (selling, general & administrative expenses and research & development expenses) for 2024 to be between $95.0 to $101.0 million, of

BenzingaMay 14 06:07

Optinose Sees 2024 XHANCE Revenue in $85M to $95M Range >OPTN

Optinose Sees 2024 XHANCE Revenue in $85M to $95M Range >OPTN

Dow JonesMay 14 06:04

Optinose Raises 2024 Guidance >OPTN

Optinose Raises 2024 Guidance >OPTN

Dow JonesMay 14 06:04

OptiNose Q1 EPS $(0.12) Misses $(0.11) Estimate, Sales $14.88M Beat $12.94M Estimate

OptiNose (NASDAQ:OPTN) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 29.41 percent increase over losses of $(0.17) pe

BenzingaMay 14 06:03

Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, Vs. Street Est of $13.7M

07:02 AM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M

MT NewswiresMay 14 06:02

Optinose 1Q Loss $14.1M >OPTN

Optinose 1Q Loss $14.1M >OPTN

Dow JonesMay 14 06:00